This is a Phase 1b/2, single-arm, open-label, multi-center, clinical study of AZD0120, a CD19/BCMA dual CAR T cell therapy, to evaluate the safety, tolerability, and efficacy in adult participants with refractory Systemic Lupus Erythematosus.
Males or females aged 18 through 70 years inclusive at the time of consent.
Written informed consent in accordance with federal, local, and institutional guidelines.
Must be able and willing to adhere to the study visit schedule and other protocol requirements
Adequate hepatic, renal, pulmonary, and cardiac function
None
AstraZeneca
Lead sponsor